<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03150524</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00130191</org_study_id>
    <nct_id>NCT03150524</nct_id>
  </id_info>
  <brief_title>RCVS: The Rational Approach to Diagnosis and Treatment</brief_title>
  <official_title>RCVS: The Rational Approach to Diagnosis and Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized clinical trial of short-acting nimodipine versus twice daily extended
      release verapamil to treat patients presenting with Reversible Cerebral Vasoconstriction
      Syndrome (RCVS).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients greater than 18 years of age presenting with clinical signs and symptoms consistent
      with RCVS (see inclusion criteria) will be enrolled. Neuroimaging (CT, Magnetic Resonance
      (MR), or 4 vessel angiogram) will be obtained along with a baseline transcranial doppler
      ultrasound (TCD). They will subsequently be randomized to receive nimodipine (every 4 hours)
      or extended release verapamil (twice daily). Mean cerebral blood flow velocities will be
      followed for reduction or normalization on daily TCD and medication dosing adjusted
      appropriately. Patients will be followed 90 days post-discharge at which time they will
      undergo repeat neuroimaging to confirm resolution of vascular abnormalities and repeat
      evaluation. To determine effectiveness, the investigators will evaluate both short-term
      (surrogate) in-hospital outcomes and long-term outcomes. Reduction of TCD velocities and
      headache severity will serve as our short-term surrogate outcomes; however, need for
      additional medications, blood pressure, new/recurrent stroke/Intracranial Hemorrhage (ICH)
      will also be evaluated along with modified Rankin score (mRS) on discharge, length of stay,
      and discharge disposition. At 90 days, the investigators will also assess headache control
      along with mRS.. Adverse events and their relation to the treatment arms will be assessed,
      and adherence to the medications will be evaluated.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2017</start_date>
  <completion_date type="Anticipated">May 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peak TCD velocities</measure>
    <time_frame>daily from admission to discharge (approx 5-7 days)</time_frame>
    <description>Peak mean Cerebral Blood Flow velocity (CBFV) in anterior circulation vessels (MCA/Anterior Cerebral Artery (ACA)/Posterior Cerebral Artery (PCA)/internal carotid)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of elevated TCD velocities</measure>
    <time_frame>daily from admission to discharge (approx 5-7 days)</time_frame>
    <description>Duration of elevated velocity (number of days from presentation to normalization/reduction)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Normalization of TCD velocities</measure>
    <time_frame>daily from admission to discharge (approx 5-7 days)</time_frame>
    <description>Normalization/reduction of velocity (yes/no)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Peak pain score</measure>
    <time_frame>every 8 hours while hospitalized (approx 5-7 days) and at 90 day follow-up</time_frame>
    <description>Peak pain score- Likert scale evaluating headache: 0-10 points</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days to pain resolution</measure>
    <time_frame>every 8 hours while hospitalized (approx 5-7 days) and at 90 day follow-up</time_frame>
    <description>Number of days to resolution</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New or recurrent stroke/hemorrhage</measure>
    <time_frame>daily through hospitalization (approx 5-7 days)</time_frame>
    <description>evaluated by neurological examinations and confirmed by imaging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Rankin Scale</measure>
    <time_frame>on hospital discharge and at 90 day follow-up</time_frame>
    <description>functional outcome scale based on mobility and ability to perform activities of daily living- scale 0-6 points (0-2 considered good outcome)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Repeat neuroimaging</measure>
    <time_frame>at 90 day follow-up</time_frame>
    <description>repeat neuroimaging to confirm reversibility of vasculopathy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medication compliance</measure>
    <time_frame>daily throughout hospitalization (approx 5-7 days) and at 90 day follow-up</time_frame>
    <description>ability to tolerate and adhere to medication</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Reversible Cerebral Vasoconstriction Syndrome</condition>
  <arm_group>
    <arm_group_label>Nimodipine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in group one will receive short-acting nimodipine every 4 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Verapamil ER</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in group two will receive long-acting verapamil every 12 hours.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>TCD- cerebral blood flow velocities</intervention_name>
    <description>Participants will undergo daily TCD for monitoring of cerebral blood flow.</description>
    <arm_group_label>Nimodipine</arm_group_label>
    <arm_group_label>Verapamil ER</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Headache pain score</intervention_name>
    <description>Participants will be evaluated by nurses for headache frequency and severity every shift.</description>
    <arm_group_label>Nimodipine</arm_group_label>
    <arm_group_label>Verapamil ER</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Neurological examination</intervention_name>
    <description>Patients will be examined routinely for evidence of neurological improvement/decline and/or evidence of a complication such as stroke or hemorrhage.</description>
    <arm_group_label>Nimodipine</arm_group_label>
    <arm_group_label>Verapamil ER</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Repeat Neuroimaging</intervention_name>
    <description>All patients will also be seen at 90 days (+/- 30 days) and administered a headache diary, repeat neuroimaging, and neurological examination.</description>
    <arm_group_label>Nimodipine</arm_group_label>
    <arm_group_label>Verapamil ER</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nimodipine</intervention_name>
    <description>Participants will be administered nimodipine every 4 hours.</description>
    <arm_group_label>Nimodipine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Verapamil ER</intervention_name>
    <description>Participants will be administered long acting verapamil every 12 hours.</description>
    <arm_group_label>Verapamil ER</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Patients 18 years of age or greater meeting the following inclusion criteria adapted from
        Singhal and colleagues 2 will be included:

        1. presentation consistent with RCVS :

          -  acute thunderclap/severe headache and

             **supporting clinical features should prompt increased clinical suspicion (eg.,
             potential medication trigger, recent pregnancy, migraine history)**

          -  evidence of beading/elevated velocities on imaging (Transcranial Doppler (TCD),
             angiogram, Computer Tomography Angiogram (CTA), MRA) and

          -  reversibility (by 90 days)-will not be required for inclusion but will be
             retrospectively adjudicated

        Participants will be excluded from the study if they are:

          -  unable to consent AND no family present to consent, or

          -  have presence of aneurysmal, traumatic, or mesencephalic Subarachnoid Hemorrhage
             (SAH), or

          -  have presence of other supported diagnosis (eg., vasculitis- inflammatory lumbar
             puncture) or

          -  are currently pregnant or

          -  the use of nimodipine or verapamil is contraindicated for any reason (eg., allergy,
             breast feeding) or

          -  have limited TCD sonographic window

               -  stroke or ICH/SAH on presentation will not be a contraindication to inclusion in
                  the trial **
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elisabeth B Marsh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rafael H Llinas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Elisabeth B Marsh, MD</last_name>
    <phone>4105508703</phone>
    <email>ebmarsh@jhmi.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rafael H Llinas, MD</last_name>
    <phone>4105501042</phone>
    <email>rllinas@jhmi.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Johns Hopkins Bayview Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elisabeth B Marsh, MD</last_name>
      <phone>410-550-8703</phone>
      <email>ebmarsh@jhmi.edu</email>
    </contact>
    <contact_backup>
      <last_name>Rafael H Llinas, MD</last_name>
      <phone>410-550-1042</phone>
      <email>rllinas@jhmi.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elisabeth B Marsh, MD</last_name>
      <phone>410-550-8703</phone>
      <email>ebmarsh@jhmi.edu</email>
    </contact>
    <contact_backup>
      <last_name>Rafael H Llinas, MD</last_name>
      <phone>410-550-1042</phone>
      <email>rllinas@jhmi.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.hopkinsmedicine.org/neurology_neurosurgery/centers_clinics/cerebrovascular/stroke/team.html</url>
    <description>Johns Hopkins School of Medicine Stroke Division Website</description>
  </link>
  <reference>
    <citation>Singhal AB, Hajj-Ali RA, Topcuoglu MA, Fok J, Bena J, Yang D, Calabrese LH. Reversible cerebral vasoconstriction syndromes: analysis of 139 cases. Arch Neurol. 2011 Aug;68(8):1005-12. doi: 10.1001/archneurol.2011.68. Epub 2011 Apr 11.</citation>
    <PMID>21482916</PMID>
  </reference>
  <reference>
    <citation>Marsh EB, Ziai WC, Llinas RH. The Need for a Rational Approach to Vasoconstrictive Syndromes: Transcranial Doppler and Calcium Channel Blockade in Reversible Cerebral Vasoconstriction Syndrome. Case Rep Neurol. 2016 Jul 29;8(2):161-171. eCollection 2016 May-Aug.</citation>
    <PMID>27721780</PMID>
  </reference>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 8, 2017</study_first_submitted>
  <study_first_submitted_qc>May 9, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 12, 2017</study_first_posted>
  <last_update_submitted>August 21, 2017</last_update_submitted>
  <last_update_submitted_qc>August 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stroke</keyword>
  <keyword>RCVS</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Verapamil</mesh_term>
    <mesh_term>Nimodipine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

